251 related articles for article (PubMed ID: 24063248)
1. The prognostic value of Her4 receptor isoform expression in triple-negative and Her2 positive breast cancer patients.
Machleidt A; Buchholz S; Diermeier-Daucher S; Zeman F; Ortmann O; Brockhoff G
BMC Cancer; 2013 Sep; 13():437. PubMed ID: 24063248
[TBL] [Abstract][Full Text] [Related]
2. The HER4 isoform JM-a/CYT2 relates to improved survival in bladder cancer patients but only if the estrogen receptor α is not expressed.
Munk M; Memon A; Poulsen SS; Borre M; Nexo E; Sorensen BS
Scand J Clin Lab Invest; 2013 Sep; 73(6):503-13. PubMed ID: 24015958
[TBL] [Abstract][Full Text] [Related]
3. Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors.
Frogne T; Laenkholm AV; Lyng MB; Henriksen KL; Lykkesfeldt AE
Breast Cancer Res; 2009; 11(1):R11. PubMed ID: 19239686
[TBL] [Abstract][Full Text] [Related]
4. HER4 isoform CYT2 and its ligand NRG1III are expressed at high levels in human colorectal cancer.
Guo Y; Duan Z; Jia Y; Ren C; Lv J; Guo P; Zhao W; Wang B; Zhang S; Li Y; Li Z
Oncol Lett; 2018 May; 15(5):6629-6635. PubMed ID: 29616125
[TBL] [Abstract][Full Text] [Related]
5. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
[TBL] [Abstract][Full Text] [Related]
6. The localization of HER4 intracellular domain and expression of its alternately-spliced isoforms have prognostic significance in ER+ HER2- breast cancer.
Fujiwara S; Hung M; Yamamoto-Ibusuk CM; Yamamoto Y; Yamamoto S; Tomiguchi M; Takeshita T; Hayashi M; Sueta A; Iwase H
Oncotarget; 2014 Jun; 5(11):3919-30. PubMed ID: 25003574
[TBL] [Abstract][Full Text] [Related]
7. ErbB4 splice variants Cyt1 and Cyt2 differ by 16 amino acids and exert opposing effects on the mammary epithelium in vivo.
Muraoka-Cook RS; Sandahl MA; Strunk KE; Miraglia LC; Husted C; Hunter DM; Elenius K; Chodosh LA; Earp HS
Mol Cell Biol; 2009 Sep; 29(18):4935-48. PubMed ID: 19596786
[TBL] [Abstract][Full Text] [Related]
8. The E3 ubiquitin ligase WWP1 selectively targets HER4 and its proteolytically derived signaling isoforms for degradation.
Feng SM; Muraoka-Cook RS; Hunter D; Sandahl MA; Caskey LS; Miyazawa K; Atfi A; Earp HS
Mol Cell Biol; 2009 Feb; 29(3):892-906. PubMed ID: 19047365
[TBL] [Abstract][Full Text] [Related]
9. Comparing protein and mRNA expressions of the human epidermal growth factor receptor family in estrogen receptor-positive breast cancer.
Kurozumi S; Yamaguchi Y; Matsumoto H; Inoue K; Kurosumi M; Oyama T; Horiguchi J; Fujii T; Shirabe K
Med Mol Morphol; 2019 Jun; 52(2):90-98. PubMed ID: 30259117
[TBL] [Abstract][Full Text] [Related]
10. Cystatin M loss is associated with the losses of estrogen receptor, progesterone receptor, and HER4 in invasive breast cancer.
Ko E; Park SE; Cho EY; Kim Y; Hwang JA; Lee YS; Nam SJ; Bang S; Park J; Kim DH
Breast Cancer Res; 2010; 12(6):R100. PubMed ID: 21092257
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study.
Koutras A; Kalogeras KT; Wirtz RM; Alexopoulou Z; Bobos M; Zagouri F; Veltrup E; Timotheadou E; Gogas H; Pentheroudakis G; Pisanidis N; Magkou C; Christodoulou C; Bafaloukos D; Papakostas P; Aravantinos G; Pectasides D; Kalofonos HP; Fountzilas G
J Transl Med; 2015 May; 13():171. PubMed ID: 26021752
[TBL] [Abstract][Full Text] [Related]
12. Presence of HER4 associates with increased sensitivity to Herceptin in patients with metastatic breast cancer.
Sassen A; Diermeier-Daucher S; Sieben M; Ortmann O; Hofstaedter F; Schwarz S; Brockhoff G
Breast Cancer Res; 2009; 11(4):R50. PubMed ID: 19624808
[TBL] [Abstract][Full Text] [Related]
13. Directing HER4 mRNA expression towards the CYT2 isoform by antisense oligonucleotide decreases growth of breast cancer cells in vitro and in vivo.
Nielsen TO; Sorensen S; Dagnæs-Hansen F; Kjems J; Sorensen BS
Br J Cancer; 2013 Jun; 108(11):2291-8. PubMed ID: 23695025
[TBL] [Abstract][Full Text] [Related]
14. A novel juxtamembrane domain isoform of HER4/ErbB4. Isoform-specific tissue distribution and differential processing in response to phorbol ester.
Elenius K; Corfas G; Paul S; Choi CJ; Rio C; Plowman GD; Klagsbrun M
J Biol Chem; 1997 Oct; 272(42):26761-8. PubMed ID: 9334263
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the prognostic value of all four HER family receptors in patients with metastatic breast cancer treated with trastuzumab: A Hellenic Cooperative Oncology Group (HeCOG) study.
Koutras A; Lazaridis G; Koliou GA; Kouvatseas G; Christodoulou C; Pectasides D; Kotoula V; Batistatou A; Bobos M; Tsolaki E; Papadopoulou K; Pentheroudakis G; Papakostas P; Pervana S; Petraki K; Chrisafi S; Razis E; Psyrri A; Bafaloukos D; Kalogeras KT; Kalofonos HP; Fountzilas G
PLoS One; 2018; 13(12):e0207707. PubMed ID: 30521571
[TBL] [Abstract][Full Text] [Related]
17. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer.
Witton CJ; Reeves JR; Going JJ; Cooke TG; Bartlett JM
J Pathol; 2003 Jul; 200(3):290-7. PubMed ID: 12845624
[TBL] [Abstract][Full Text] [Related]
18. Analysis of HER Family (HER1-4) Expression as a Biomarker in Combination Therapy with Pertuzumab, Trastuzumab and Docetaxel for Advanced HER2-positive Breast Cancer.
Takada K; Kashiwagi S; Goto W; Asano Y; Morisaki T; Fujita H; Takashima T; Ohsawa M; Hirakawa K; Ohira M
Anticancer Res; 2018 Apr; 38(4):2285-2294. PubMed ID: 29599351
[TBL] [Abstract][Full Text] [Related]
19. The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: a study in bladder cancer patients.
Memon AA; Sorensen BS; Meldgaard P; Fokdal L; Thykjaer T; Nexo E
Br J Cancer; 2006 Jun; 94(11):1703-9. PubMed ID: 16685269
[TBL] [Abstract][Full Text] [Related]
20. Analysis of differentially expressed proteins between HER2 positive and triple negative breast cancer and their prognostic significance.
Wei Z; Sijia F; Rui T; Yang L; Jianjun H; Bin W; Jing X
Ann Diagn Pathol; 2021 Dec; 55():151834. PubMed ID: 34610510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
